A note to physicians. AIDS in Arkansas

As a more complete safety profile of ddI begins to merge, it is clear that this agent continues to hold promise as an option for the treatment of primary HIV disease in certain patients. The long-term efficacy and safety of the drug can be fully understood only from the results of controlled clinical trials. To speed this process, the assistance and cooperation of all physicians in identifying and referring patients to the controlled trials is requested. Completion of these studies is essential and critical to a full understanding of the use of this drug in the treatment of patients with HIV infection.